

# Anti-CD40 Antibody - Pipeline Insight, 2022

<https://marketpublishers.com/r/A969D3A2F275EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A969D3A2F275EN

## Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Anti-CD40 Antibody - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD40 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Anti-CD40 Antibody Understanding

#### Anti-CD40 Antibody: Overview

CD40 is a 48?kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. It is also found on a large portion of melanomas and carcinomas of the lung, breast, colon, prostate, pancreas, kidney, ovary, and head and neck as well as all of B cell malignancies (1–4). The ligand for CD40 (CD154 or CD40L) is expressed on activated T cells and platelets.

Function - The protein receptor encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been found to be essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.[5] AT-hook

transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions.

Anti-CD40 Antibody - CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. Agonistic CD40 antibodies have been shown to substitute for T cell help provided by CD4+ lymphocytes in murine models of T cell-mediated immunity.

### Anti-CD40 Antibody Emerging Drugs Chapters

This segment of the Anti-CD40 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Anti-CD40 Antibody Emerging Drugs

#### ABBV-927: AbbVie

ABBV-927 is an agonistic anti-CD40 monoclonal antibody that is being investigated in a Phase 1 clinical trial for solid tumors and in phase I/II for pancreatic cancer.

#### GEN1042: Mirati Therapeutics

DuoBody®-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab's DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody® format.

#### Sotigalimab: Apexigen

Sotigalimab is a novel, humanized monoclonal antibody that stimulates the anti-tumor

immune response. Sotigalimab targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of Sotigalimab to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. Sotigalimab is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Further product details are provided in the report.....

### Anti-CD40 Antibody: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD40 Antibody drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Anti-CD40 Antibody

There are approx. 10+ key companies which are developing the Anti-CD40 Antibody. The companies which have their Anti-CD40 Antibody drug candidates in the most advanced stage, i.e. phase II include, Apexigen.

#### Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anti-CD40 Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD40 Antibody: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD40 Antibody therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD40 Antibody drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD40 Antibody R&D. The therapies under development are focused on novel approaches for Anti-CD40 Antibody.

Anti-CD40 Antibody Report Insights

Anti-CD40 Antibody Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Anti-CD40 Antibody Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Anti-CD40 Antibody drugs?

How many Anti-CD40 Antibody drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD40 Antibody?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD40 Antibody therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anti-CD40 Antibody and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

AbbVie

Genmab

Apexigen

Kiniksa Pharmaceuticals

Eledon Pharmaceuticals

Seagen

Celldex

Eucure Biopharma

Glycotope

Biogen

Astellas Pharma

Kyowa Kirin

Boston Immune Technologies and Therapeutics

Bristol-Myers Squibb

## Key Products

ABBV-927

GEN 1042

Sotigalimab

KPL 404

AT-1501

SEA-CD40

CDX-1140

YH003

CD40-GEX

Dapirolizumab pegol

Bleselumab

BITD 401412

BMS 986325



## Contents

Introduction

Executive Summary

Anti-CD40 Antibody: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Anti-CD40 Antibody – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Anti-CD40 Antibody companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Anti-CD40 Antibody Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Dapirolizumab pegol: Biogen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Sotigalimab : Apexigen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

**GEN 1042: Genmab**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

**BITD 401412: Boston Immune Technologies and Therapeutics**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Anti-CD40 Antibody Key Companies

Anti-CD40 Antibody Key Products

Anti-CD40 Antibody- Unmet Needs

Anti-CD40 Antibody- Market Drivers and Barriers

Anti-CD40 Antibody- Future Perspectives and Conclusion

Anti-CD40 Antibody Analyst Views

Anti-CD40 Antibody Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Anti-CD40 Antibody

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Anti-CD40 Antibody
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Anti-CD40 Antibody - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A969D3A2F275EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A969D3A2F275EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970